CIK 0001133416
- Non-accelerated filer
- Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 043562325
- Phone
- +1 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- 4 Planned sale President and CEO sold 22,463 shares at an average $6.07 ($136,366)
- 4 Planned sale Chief Financial Officer sold 77,920 shares at an average $6.15 ($478,849)
- 4 Planned sale Chief Medical Officer sold 121,117 shares at $5.47 ($662,510)
- 4 Open-market sale 10% owner sold 40,000 shares at $5.25 ($210,000)
- 4 Planned sale President and CEO sold 1,867 shares at $6.03 ($11,252)
- 4 Planned sale Chief Financial Officer sold 5,291 shares at an average $6.03 ($31,884)
- 4 Planned sale President and CEO sold 200 shares at $6.00 ($1,200)
- 4 Planned sale Chief Financial Officer sold 600 shares at $6.00 ($3,600)
- 4 Planned sale President and CEO sold 15,720 shares at an average $6.07 ($95,342)
- 4 Planned sale Chief Financial Officer sold 32,439 shares at an average $6.06 ($196,676)
- 4 Open-market sale 10% owner sold 50,000 shares at an average $4.94 ($246,800)
- 5 Insider Annual Insider Trading Report
- 4 Planned sale Chief Financial Officer sold 8,706 shares at $6.44 ($56,054)
- 4 Planned sale President and CEO sold 14,000 shares at $6.36 ($89,048)
- 4 Open-market buy Director bought 1,000 shares at $2.93 ($2,925)
- 4 Open-market buy Director bought 5,000 shares at $2.90 ($14,495)
- 4 Option exercise 10% owner acquired 323,125 shares (option exercise)
- 5 Insider Annual Insider Trading Report
- 4 Grant or award President and CEO acquired 56,420 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 3 of 39 · 776 filings